Related Experiment Video
Updated: Feb 22, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report
Peng Song1, Jing Yang, Xiaomei Li
1Department of Geriatric Oncology Department of Geriatric Radiology, The General Hospital of Chinese People's liberation Army, Beijing, China.
Rationale:
Molecular targeted therapy provides new ideas and hope for the treatment of hepatocellular cancer. Epidermal growth factor receptor (EGFR) is closely related to tumor cell proliferation, apoptosis, invasion, and metastasis.
Patient Concerns:
Several reports indicate that the EGFR is expressed frequently in hepatocellular carcinoma (HCC), thus targeting EGFR research has become a hot topic to explore the treatment of HCC patient.
Diagnoses:
Anti-EGFR might serve as a potential therapeutic agent, especially for patients with HCC who are unable to tolerate chemotherapy and surgery.
Interventions:
Although phase II open-label study of cetuximab in unresectable HCC was negative, the clinical relevance of this report by Song et al which is based on a single patient is questionable.
Outcomes:
We for the first time report that nimotuzumab (an anti-EGFR mAb) resulted in a complete remission (CR) in an 87-year-old patient with HCC. The patient was in B stage according to Barcelona center staging criteria and his liver function was Child-Pugh B grade.
Lessons:
Our case suggested that anti-EGFR mAbs might be potential therapeutic options for HCC.
Insights
Nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, achieved complete remission in an elderly hepatocellular carcinoma (HCC) patient. This suggests anti-EGFR therapies show promise for HCC treatment.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Hepatocellular carcinoma (HCC) treatment landscape.
- Epidermal Growth Factor Receptor (EGFR) role in cancer progression.
Observation:
- EGFR is frequently expressed in HCC.
- Anti-EGFR therapies offer alternatives for patients intolerant to chemotherapy or surgery.
Findings:
- Nimotuzumab, an anti-EGFR monoclonal antibody (mAb), achieved complete remission in an 87-year-old HCC patient.
- The patient had advanced HCC (B stage) and impaired liver function (Child-Pugh B).
Implications:
- Anti-EGFR mAbs represent a potential therapeutic strategy for HCC.
- Further investigation into anti-EGFR mAbs for HCC is warranted.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:55Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016